

Supplementary Table 3. EAIRs (95% CI) of IBD over the entire treatment period for patients receiving secukinumab 150 mg or secukinumab 300 mg

	PsO Studies		PsA Studies		AS Studies	
	150 mg	300 mg	150 mg	300 mg	150 mg	300 mg
Total exposure, PY	3815.5	6601.4	1913.1	940.9	961.8	196.0
Incidence, identified by standard definition (Preferred Term)						
	150 mg	300 mg	150 mg	300 mg	150 mg	300 mg
CD, EAIR per 100 PY [95% CI]	0.05 [0.01, 0.19]	0.05 [0.01, 0.13]	0.0 [0.0, 0.2]	0.1 [0.0, 0.6]	0.2 [0.0, 0.8]	0.0 [0.0, 1.9]
UC, EAIR per 100 PY [95% CI]	0.16 [0.06, 0.34]	0.12 [0.05, 0.24]	0.1 [0.0, 0.3]	0.1 [0.0, 0.6]	0.2 [0.0, 0.8]	0.0 [0.0, 1.9]
IBDU, EAIR per 100 PY [95% CI]	0.03 [0.00, 0.15]	0.00 [0.00, 0.06]	0.0 [0.0, 0.2]	0.2 [0.0, 0.8]	0.0 [0.0, 0.4]	0.0 [0.0, 1.9]

AS, ankylosing spondylitis; CI, confidence interval; CD, Crohn's disease ; EAIR, exposure-adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PsA, psoriatic arthritis; PsO, psoriasis; PY, patient-years; UC, ulcerative colitis